A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Breast Neoplasms, Male

abstract

  • In combination with weekly paclitaxel, the recommended phase II dose of dasatinib is 120 mg daily and preliminary activity has been seen in patients with MBC.

publication date

  • December 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4643618

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdr018

PubMed ID

  • 21406471

Additional Document Info

start page

  • 2575

end page

  • 81

volume

  • 22

number

  • 12